🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

242 results for “ANI” Clear

  1. An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).

    Pharma Mar S.A.

    Glioblastoma

    phase 1 other active

    1 trial

  2. Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions

    BIAL - Portela & Ca

    No medical condition.

    phase 1 other active

    1 trial

  3. Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.

    BIAL - Portela & Ca

    No medical condition.

    phase 1 other active

    1 trial

  4. Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.

    BIAL - Portela & Ca

    No medical condition.

    phase 1 other active

    1 trial

  5. Bumetanide

    CATALYST PHARMACEUTICALS, INC.

    Seizures

    phase 1 small molecule completed

    1 trial

  6. Camel milk containing Bifidobacterium animalis A6

    China SXT Pharmaceuticals

    Type 2 Diabetes

    phase 1 other completed

    1 trial

  7. Cardiovascular safety assessment of Tanimilast in healthy volunteers

    Chiesi Farmaceutici S.p.A

    This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.

    phase 1 other active

    1 trial

  8. Clavulanic Acid

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence, in Remission

    phase 1 small molecule completed

    1 trial

  9. Clavulanic acid

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  10. Finlepsin 200 retard, 200 mg, tabletki o przedłużonym uwalnianiu, Orungal, 100 mg, kapsułki, Gemfibrozilo STADA 600 mg comprimidos recubiertos con película EFG, Neurotop retard 300, 300 mg, tabletki o przedłużonym uwalnianiu

    Minoryx Therapeutics S.L.

    Adrenoleukodystrophy

    phase 1 small molecule active

    1 trial

  11. Follicle Stimulating Hormone Receptor T Cells

    Anixa Biosciences Inc

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  12. GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

    Rani Therapeutics Holdings

    Ulcerative colitis

    phase 1 other active

    1 trial

  13. Granisetron hydrochloride 1 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  14. Humanized TNFα monoclonal antibody

    Sunshine Biopharma

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  15. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    MYELODYSPLASTIC SYNDROME; MDS

    phase 1 mab active

    1 trial

  16. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  17. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  18. Peptides (N,R&C) formulated in Montanide ISA 720

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 small molecule completed

    1 trial

  19. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Pharma Mar S.A.

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  20. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  21. Pretomanid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  22. RT-102 (80 μg)

    Rani Therapeutics Holdings

    Healthy Volunteers

    phase 1 other completed

    1 trial

  23. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani Therapeutics Holdings

    Obesity

    phase 1 other active

    1 trial

  24. RaniPill capsule containing octreotide

    Rani Therapeutics Holdings

    Healthy Volunteers

    phase 1 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources